CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy
Rolling BLA Submission Starting as Early as the End of 2018 - FDA Provides Guidance on Ongoing Requirements VANCOUVER, Washington, ...
Tag: CYDY
Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9
VANCOUVER, Washington, June 04, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announced today that results from a Phase 2b/3 trial ...
Results of CytoDyn’s PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials
Data Provide Support for PRO 140 as long-acting, HIV-1 maintenance therapy VANCOUVER, Washington, May 24, 2018 (GLOBE NEWSWIRE) -- CytoDyn ...
CytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease
VANCOUVER, Washington, Oct. 05, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody ...
CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV
VANCOUVER, Washington, Aug. 21, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody ...
CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease
VANCOUVER, Washington, May 17, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of ...
CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy
VANCOUVER, Washington, Jan. 11, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of ...
© Copyright 2022 publicwire.com